Akari Therapeutics (NASDAQ:AKTX) is a biopharmaceutical company engaged in the development of treatments for various autoimmune and inflammatory diseases. The company focuses on leveraging its innovative drug development platform to create therapies that address critical unmet medical needs, particularly in areas where inflammation plays a key role in disease progression. Akari's lead product candidate, nomacopan, is in various stages of clinical trials targeting conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atopic keratoconjunctivitis, and bullous pemphigoid. Akari's objectives are to advance the clinical development of its pipeline products, secure regulatory approvals, and ultimately improve patient outcomes in diseases with significant inflammatory components.